Search research articles
Contact Us
Filters
Showing results (51-60 of 91) with videos related to
Page
of 10
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 6, 2007
Weekly paclitaxel combined with monthly carboplatin in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study
Jean-Louis Pujol, Bernard Milleron, Olivier Molinier, et al.
Journal of Neurosurgery
|
January 19, 2024
Prognostic impact of the number and total tumor burden of secondary cerebral lesions in patients with resected brain metastases of non-small cell lung cancers
Sidonie Sauvageot, Caroline Mollevi, Quentin D Thomas, et al.
BMJ Open
|
March 15, 2013
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials
Silvy Laporte, Pierre Squifflet, Noémie Baroux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 1, 2007
Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01
Jean Louis Pujol, Jean Luc Breton, Radj Gervais, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 3, 2019
Ultra-sensitive <i>EGFR</i> <sup>T790M</sup> Detection as an Independent Prognostic Marker for Lung Cancer Patients Harboring <i>EGFR</i> <sup>del19</sup> Mutations and Treated with First-generation TKIs
Julie A Vendrell, Julien Mazieres, Romain Senal, et al.
JTO Clinical and Research Reports
|
November 8, 2021
Abemaciclib in Combination With Pembrolizumab for Stage IV <i>KRAS</i>-Mutant or Squamous NSCLC: A Phase 1b Study
Jean-Louis Pujol, Johan Vansteenkiste, Luis Paz-Ares Rodríguez, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 17, 2013
Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer
Jean-Louis Pujol, Robert Pirker, Thomas J Lynch, et al.
Clinical Lung Cancer
|
August 9, 2014
Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer
Jean-Louis Pujol, Luis Paz-Ares, Filippo de Marinis, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 23, 2011
Human immunodeficiency virus infection and non-small cell lung cancer: survival and toxicity of antineoplastic chemotherapy in a cohort study
Alain Makinson, Jean-Charles Tenon, Sabrina Eymard-Duvernay, et al.
Cancers
|
November 27, 2019
Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial
Fatéméh Dubois, Maureen Keller, Julien Hoflack, et al.
Page
of 10
Search research articles
Search
Showing results (51-60 of 91) with videos related to
Sort By:
Page
of 10
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 6, 2007
Weekly paclitaxel combined with monthly carboplatin in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study
Jean-Louis Pujol, Bernard Milleron, Olivier Molinier, et al.
Journal of Neurosurgery
|
January 19, 2024
Prognostic impact of the number and total tumor burden of secondary cerebral lesions in patients with resected brain metastases of non-small cell lung cancers
Sidonie Sauvageot, Caroline Mollevi, Quentin D Thomas, et al.
BMJ Open
|
March 15, 2013
Prediction of survival benefits from progression-free survival benefits in advanced non-small-cell lung cancer: evidence from a meta-analysis of 2334 patients from 5 randomised trials
Silvy Laporte, Pierre Squifflet, Noémie Baroux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 1, 2007
Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01
Jean Louis Pujol, Jean Luc Breton, Radj Gervais, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 3, 2019
Ultra-sensitive <i>EGFR</i> <sup>T790M</sup> Detection as an Independent Prognostic Marker for Lung Cancer Patients Harboring <i>EGFR</i> <sup>del19</sup> Mutations and Treated with First-generation TKIs
Julie A Vendrell, Julien Mazieres, Romain Senal, et al.
JTO Clinical and Research Reports
|
November 8, 2021
Abemaciclib in Combination With Pembrolizumab for Stage IV <i>KRAS</i>-Mutant or Squamous NSCLC: A Phase 1b Study
Jean-Louis Pujol, Johan Vansteenkiste, Luis Paz-Ares Rodríguez, et al.
Lung Cancer (Amsterdam, Netherlands)
|
December 17, 2013
Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small cell lung cancer
Jean-Louis Pujol, Robert Pirker, Thomas J Lynch, et al.
Clinical Lung Cancer
|
August 9, 2014
Long-term and low-grade safety results of a phase III study (PARAMOUNT): maintenance pemetrexed plus best supportive care versus placebo plus best supportive care immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer
Jean-Louis Pujol, Luis Paz-Ares, Filippo de Marinis, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 23, 2011
Human immunodeficiency virus infection and non-small cell lung cancer: survival and toxicity of antineoplastic chemotherapy in a cohort study
Alain Makinson, Jean-Charles Tenon, Sabrina Eymard-Duvernay, et al.
Cancers
|
November 27, 2019
Role of the YAP-1 Transcriptional Target cIAP2 in the Differential Susceptibility to Chemotherapy of Non-Small-Cell Lung Cancer (NSCLC) Patients with Tumor RASSF1A Gene Methylation from the Phase 3 IFCT-0002 Trial
Fatéméh Dubois, Maureen Keller, Julien Hoflack, et al.
Page
of 10